Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo
You may also be interested in...
Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir
Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories
Daiichi Sankyo Lifts FY2009 Profit Forecasts, Submits NDA For Flu Inhaler Laninamivir
Daiichi Sankyo Jan. 29 lifted profit estimations for fiscal year 2009, citing favorable exchange rates for the Indian rupee against the U.S. dollar, as well as improvements in subsidiary Ranbaxy Laboratories
Shionogi Pushes For Fast-Track Approval Of Flu Treatment Peramivir
TOKYO - Shionogi announced Sept. 30 it is preparing to submit an application for approval for influenza treatment peramivir for A/H1N1 and other varieties of flu